Literature DB >> 18242077

Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States.

Milena Sant1, Claudia Allemani, Roberta De Angelis, Antonino Carbone, Silvia de Sanjosè, Alessandro M Gianni, Pilar Giraldo, Francesca Marchesi, Rafael Marcos-Gragera, Carmen Martos-Jiménez, Marc Maynadié, Martine Raphael, Franco Berrino.   

Abstract

We explored the influence of morphology on geographic differences in 5-year survival for non-Hodgkin lymphoma (NHL) diagnosed in 1990-1994 and followed for 5years: 16,955 cases from 27 EUROCARE-3 cancer registries, and 22,713 cases from 9 US SEER registries. Overall 5-year relative survival was 56.1% in EUROCARE west, 47.1% in EUROCARE east and 56.3% in SEER. Relative excess risk (RER) of death was 1.05 (95% confidence interval (CI) 1.01-1.10) in EUROCARE west, 1.52 (95% CI 1.44-1.60) in EUROCARE east (SEER reference). Excess risk of death was significantly above reference (diffuse B lymphoma) for Burkitt's and NOS lymphoma; not different for lymphoblastic and other T-cell; significantly below reference (in the order of decreasing relative excess risk) for NHL NOS, mantle cell/centrocytic, lymphoplasmacytic, follicular, small lymphocytic/chronic lymphocytic leukaemia, other specified NHL and cutaneous morphologies. Interpretation of marked variation in survival with morphology is complicated by classification inconsistencies. The completeness and standardisation of cancer registry morphology data needs to be improved.

Entities:  

Mesh:

Year:  2008        PMID: 18242077     DOI: 10.1016/j.ejca.2007.12.016

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  7 in total

1.  Non-Hodgkin's lymphoma in the elderly.

Authors:  Paolo F Caimi; Paul M Barr; Nathan A Berger; Hillard M Lazarus
Journal:  Drugs Aging       Date:  2010-03-01       Impact factor: 3.923

2.  Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE project.

Authors:  Rafael Marcos-Gragera; Claudia Allemani; Carmen Tereanu; Roberta De Angelis; Riccardo Capocaccia; Marc Maynadie; Stefano Luminari; Stefano Ferretti; Tom Børge Johannesen; Risto Sankila; Marja-Liisa Karjalainen-Lindsberg; Arianna Simonetti; Maria Carmen Martos; Martine Raphaël; Pilar Giraldo; Milena Sant
Journal:  Haematologica       Date:  2011-02-17       Impact factor: 9.941

3.  InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions.

Authors:  Jennifer J Turner; Lindsay M Morton; Martha S Linet; Christina A Clarke; Marshall E Kadin; Claire M Vajdic; Alain Monnereau; Marc Maynadié; Brian C-H Chiu; Rafael Marcos-Gragera; Adele Seniori Costantini; James R Cerhan; Dennis D Weisenburger
Journal:  Blood       Date:  2010-08-10       Impact factor: 22.113

4.  Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010.

Authors:  Djamila E Issa; Saskia A M van de Schans; Martine E D Chamuleau; Henrike E Karim-Kos; Marielle Wondergem; Peter C Huijgens; Jan Willem W Coebergh; Sonja Zweegman; Otto Visser
Journal:  Haematologica       Date:  2014-12-15       Impact factor: 9.941

5.  Long-term time trends in incidence, survival and mortality of lymphomas by subtype among adults in Manitoba, Canada: a population-based study using cancer registry data.

Authors:  Xibiao Ye; Salaheddin Mahmud; Pamela Skrabek; Lisa Lix; James B Johnston
Journal:  BMJ Open       Date:  2017-07-17       Impact factor: 2.692

6.  Causes of mortality in cases with extra nodal natural killer/T-cell lymphoma, nasal type: A cohort study.

Authors:  Mei Mei; Yingjun Wang; Mingzhi Zhang
Journal:  PLoS One       Date:  2019-04-17       Impact factor: 3.240

7.  Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China.

Authors:  Yuankai Shi; Ying Han; Jianliang Yang; Peng Liu; Xiaohui He; Changgong Zhang; Shengyu Zhou; Liqiang Zhou; Yan Qin; Yongwen Song; Yueping Liu; Shulian Wang; Jing Jin; Lin Gui; Yan Sun
Journal:  Chin J Cancer Res       Date:  2019-02       Impact factor: 5.087

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.